Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.
Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program. As of March 17, 2025, the company has bought back a total of 1,603,251 ordinary fully paid securities, with 35,093 acquired on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing primarily on the development of therapies for neurological disorders. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: -2.18%
Average Trading Volume: 670
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $955.7M
See more data about NEU stock on TipRanks’ Stock Analysis page.